Comprehensive Genomic Analysis for Identifying FZD6 as a Novel Diagnostic Biomarker for Acute Myeloid Leukemia

Figure 4

High FZD6 expression is related to poor OS in AML patients. (a) The association between FZD6 and OS of AML patients on the GEPIA website. (b) The association between FZD6 and OS of AML patients based on the cBioPortal TCGA database. (c) The association between HSCT and OS of AML patients. (d) The association between FZD6 and OS of AML patients did not receive HSCT. (e) The association between FZD6 and OS of AML patients received HSCT. (f) The association between FZD6 and OS of AML patients with intermediate/adverse risk did not receive HSCT.

(a)

(b)

(c)

(d)

(e)

(f)